Timothy Yap, MD
Medical Oncology · Houston, TXNPI 1942743216
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $255,235 of the $315,964 with a category attached, or 80.8%. 26 manufacturers reported payments, led by Bayer at 30.6% of the total. Reporting peaked in 2022 at $83,561 and has fallen 53.0% since, to $39,242 in 2025. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $1755.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$97K
- E.r. Squibb & Sons, L.L.C.$27K
- Pfizer$27K
- Astrazeneca UK Limited$22K
- EMD Serono, Inc.$20K
- GSK$20K
- plus $104K from 20 others
Across 2,558 payments — averaging $22,067 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$23.2M
- AstraZeneca$5M
- GSK$4.7M
- Merck$4.3M
- Bayer$4.2M
- Astrazeneca UK Limited$1.4M
- plus $13.6M from 24 others
What the payments were for
- Consulting fees$255,23581%
- Speaking & faculty fees$16,9205%
- Travel & lodging$41,17613%
- Food & beverage$2,6321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 49 | $96,777 |
| E.r. Squibb & Sons, L.L.C. | 18 | $26,896 |
| Pfizer | 22 | $26,642 |
| Astrazeneca UK Limited | 8 | $21,530 |
| EMD Serono, Inc. | 20 | $19,910 |
| GSK | 10 | $19,866 |
| F. Hoffmann-la Roche AG | 4 | $18,683 |
| Merck | 9 | $13,703 |
| EMD Serono Research & Development Institute, Inc. | 3 | $12,962 |
| Merck Kgaa | 3 | $12,486 |
| Siemens Medical Solutions USA, Inc. | 4 | $8,318 |
| Amgen | 1 | $7,788 |
| Otsuka Pharmaceutical Co., Ltd. | 3 | $4,012 |
| AstraZeneca | 6 | $3,852 |
| Sanofi US Services Inc. | 1 | $3,745 |
| Jazz Pharmaceuticals Inc. | 3 | $3,296 |
| Daiichi Sankyo Inc. | 1 | $2,911 |
| AbbVie | 2 | $2,822 |
| Blueprint Medicines Corporation | 3 | $2,684 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,900 |
| Institut DE Recherches Internationales Servier | 2 | $1,700 |
| Kyowa Kirin, Inc. | 2 | $1,470 |
| Varian Medical Systems, Inc. | 2 | $1,300 |
| Tersera Therapeutics LLC | 1 | $681 |
| Boehringer Ingelheim | 1 | $20 |
| Genentech, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$315,964 in reported general payments places this provider in the 90th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.